Select Page

Ankyra is developing a platform to significantly improve both the safety and efficacy of cytokine immunotherapies for cancer. Systemic dosing of these powerful immune stimulants has historically been limited by broad immune activation and toxicity. We have developed methods to localize cytokines specifically and persistently within tumors thereby creating intense hot spots of inflammation that activate a comprehensive anti-tumor immune response. Our mission is to translate this approach into the clinic and demonstrate superior efficacy compared to available options.

Management Team

Tillman Gerngross, Ph.D.

Tillman Gerngross, Ph.D.

President and Co-Founder

Dane Wittrup, Ph.D.

Dane Wittrup, Ph.D.

Co-founder

Darrell Irvine, Ph.D.

Darrell Irvine, Ph.D.

Co-founder

Michael Schmidt, Ph.D.

Michael Schmidt, Ph.D.

Chief Scientific Officer

Gregory Zarbis-Papastoitsis, Ph.D.

Gregory Zarbis-Papastoitsis, Ph.D.

EVP of Process and Manufacturing Sciences

Board of Directors

Tillman Gerngross, Ph.D.Co-Founder & CEO of Adagio andAdimab, LLC

Terry McGuirePartner, Polaris Partners

Ajay RoyanPartner, Mithril Capital

83 Newbury Street • 4th Floor Boston, MA 02116